(March 15, 2016, 1:09 PM EDT) -- WASHINGTON, D.C. — In a March 11 order, the Federal Circuit U.S. Court of Appeals revealed that its rehearing of a patent dispute over the anti-coagulant drug bivalirudin will be reheard May 5 at 10 a.m. (The Medicines Company v. Hospira Inc., et al., Nos. 14-1469, -1504, Fed. Cir.)....